Novacyt
S.A.
("Novacyt", the "Company" or
the "Group")
Directorate change
Dr John
Brown CBE appointed as Chairman
Paris, France,
and Eastleigh and Manchester, UK - 26 September 2024
- Novacyt S.A. (EURONEXT GROWTH: ALNOV; AIM:
NCYT), an international molecular diagnostics company with a broad
portfolio of integrated technologies and services, announces the
appointment of Dr John Brown CBE as
Chairman effective from 1 October 2024. Dr Brown was appointed
Non-executive Director of Novacyt in September 2023 following the
acquisition of Yourgene Health and will succeed James
Wakefield, who is retiring from the Board having been Chairman
since before the company joined AIM in 2017.
Dr Brown has over 38 years industry
experience, which includes significant capital markets and board
experience in the healthcare and life sciences sector. He is
currently Chairman of Laverock Therapeutics Ltd and Calcivis Ltd,
and until recently was Chairman of Synpromics Ltd, BioCity Group
and the Cell and Gene Therapy Catapult. Previously, he was Chairman
of Kyowa Kirin International plc, BTG plc, Axis-Shield plc, Touch
Bionics Ltd and CXR Biosciences Ltd and Senior Non-Executive
Director of Quantum Pharma plc. Dr Brown was appointed to the Board
of Yourgene Health in July 2019 as a Non-executive Director and
became Chairman in April 2022.
Dr John Brown
CBE
Chairman of Novacyt
S.A.
Lyn
Rees, CEO of Novacyt, commented: "It is a pleasure to have
John stepping into the role of Chairman at Novacyt. John has
a proven track record of successfully building life sciences
companies and his wealth of knowledge in capital markets and the
life sciences sector will be important as we look to execute the
strategic plan of the combined business.
"I
would like to thank James for his contribution and leadership of
Novacyt, especially navigating the business through the pandemic
and its aftereffects. Under James' tenure, the business has made a
series of successful acquisitions, including Primerdesign and more
recently Yourgene Health. James leaves the business in a strong
financial position, with significant cash resources and a broad
portfolio of molecular diagnostics products and
services."
Dr
John Brown, Incoming Chairman said: "I am delighted to be
appointed Chairman of Novacyt. The Group has a strong and diverse
portfolio of differentiated molecular diagnostic products,
established sales channels and a world-class team of experts. I
look forward to continuing to work with Lyn and the rest of the
Board as we drive the business through the next stage of
development."
This announcement contains inside information
for the purposes of Article 7 of Regulation (EU)
596/2014.
Contacts
|
Novacyt SA
|
https://novacyt.com/investors
|
|
Lyn Rees, Chief Executive
Officer
|
Via Walbrook
PR
|
|
Steve Gibson, Chief Financial
Officer
|
|
|
SP
Angel Corporate Finance LLP (Nominated Adviser and
Broker)
|
+44 (0)20
3470 0470
|
|
Matthew Johnson / Charlie Bouverat
(Corporate Finance)
Vadim Alexandre / Rob Rees
(Corporate Broking)
|
|
|
|
|
|
Deutsche Numis (Joint
Broker)
|
+44 (0)20
7260 1000
|
|
Freddie Barnfield / Duncan Monteith
/ Michael Palser
|
|
|
|
|
|
Allegra Finance (French Listing Sponsor)
Rémi Durgetto / Yannick
Petit
|
+33 (1) 42 22 10 10
r.durgetto@allegrafinance.com
/
y.petit@allegrafinance.com
|
|
|
|
|
Walbrook PR
(Financial PR & IR)
Stephanie Cuthbert / Paul McManus
/
Phillip Marriage / Alice
Woodings
|
+44 (0)20
7933 8780 or novacyt@walbrookpr.com
+44
(0)7796 794 663 / +44 (0)7980 541 893
+44
(0)7867 984 082 / +44 (0)7407 804 654
|
|
|
|
|
| |
About Novacyt Group (www.novacyt.com)
Novacyt is an international
molecular diagnostics company providing a broad portfolio of
integrated technologies and services, primarily focused on the
delivery of genomic medicine. The
Company develops, manufactures, and
commercialises a range of molecular assays
and instrumentation to deliver workflows and services that enable
seamless end-to-end solutions from sample to result across multiple
sectors including human health, animal health and environmental.
The Company is divided into three
business segments:
|
Clinical
|
Broad portfolio of human clinical
in vitro diagnostic
products, workflows and services focused on three therapeutic
areas:
·
Reproductive Health: NIPT, Cystic Fibrosis and
other rapid aneuploidy tests
·
Precision Medicine: DPYD genotyping
assay
·
Infectious Diseases: Winterplex, multiplex winter
respiratory PCR panel
|
|
Instrumentation
|
Portfolio of next generation size
selection DNA sample preparation platforms and rapid
PCR machines, including:
·
Ranger® Technology: automated DNA sample
preparation and target enrichment technology
·
MyGo: real-time quantitative PCR (qPCR)
instruments
|
|
Research Use Only
|
Range of services for the life
sciences industry:
·
Design, manufacture, and supply of
high-performance qPCR assays and workflows for use in human health,
agriculture, veterinary and environmental, to support global health
organisations and the research industry
·
Pharmaceutical research services: whole genome
sequencing (WGS) / whole exome sequencing (WES)
|
Novacyt is headquartered in
Vélizy-Villacoublay in France with offices in the UK (in Stokesley,
Eastleigh and Manchester), Singapore, the US and Canada and has a
commercial presence in over 65 countries. The Company is listed on
the London Stock Exchange's AIM market ("NCYT") and on the Paris
Stock Exchange Euronext Growth ("ALNOV").
For more information, please refer
to the website: www.novacyt.com